← Back to Search

Minocycline for Schizophrenia

N/A
Waitlist Available
Led By Mujeeb U Shad, MD, MSCS
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages between 18-35 years
Current DSM-IV diagnosis of schizophrenia or schizoaffective disorder confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.) conducted by a trained psychiatrist.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 8, and week 16 of the study
Awards & highlights

Study Summary

This study aims to examine the efficacy of minocycline augmentation in a sample of moderately ill outpatients with early-course schizophrenia on their chlorpromazine-equivalent doses of second-generation antipsychotic medications. The investigators hypothesize that as compared to placebo a 2-month treatment with minocycline in 120 volunteers with early-course schizophrenia will result in a more significant improvement in psychopathology (primary outcome) and cognitive symptoms (secondary outcome). In addition, cytokine plasma levels will be used as another secondary outcome measure to see if treatment-induced changes in total PANSS score are associated with changes in cytokine levels.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 8, and week 16 of the study
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 8, and week 16 of the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment-induced change in total score on Positive and Negative Syndrome Scale (PANSS)
Secondary outcome measures
Treatment-induced change in MATRICS Cognitive Consensus Battery (MCCB)
Treatment-induced changes in plasma level of cytokines

Side effects data

From 2016 Phase 4 trial • 10 Patients • NCT02124811
40%
Inpatient psychiatric hospitalization
20%
Hospitalization due to ischemic colitis
20%
Hypotension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Low CRP
High CRP

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MinocyclineExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minocycline
FDA approved

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
902 Previous Clinical Trials
321,001 Total Patients Enrolled
3 Trials studying Schizophrenia
65 Patients Enrolled for Schizophrenia
Stanley Medical Research InstituteOTHER
140 Previous Clinical Trials
10,276 Total Patients Enrolled
83 Trials studying Schizophrenia
6,226 Patients Enrolled for Schizophrenia
Mujeeb U Shad, MD, MSCSPrincipal InvestigatorUT Health Sciences Center at Houston
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby Mar 2025